Voluntis Collaborates with Novartis to Evaluate the Use of Digital Therapeutic Platform for Breast Cancer
Voluntis announced today a collaboration with Novartis to evaluate the use of Voluntis’ digital therapeutic platform for Breast Cancer patients with the goal to empower patients with tools to more effectively manage symptoms and, thereby, improve patient experience and outcomes. This collaboration will leverage Voluntis’ Theraxium Oncology, the company’s core platform for digital therapeutics in the field of oncology.
In addition to enabling self-management of symptoms, data analytics and automated triage capabilities will make it possible for integrated care teams to monitor patients remotely and engage directly with them at the appropriate time. The digital therapeutic will be evaluated in an upcoming prospective clinical trial. The new collaboration uses Voluntis’ multi-disciplinary expertise in implementing digital therapeutics intended to support real-world use of a cancer therapy.
“We are delighted to work with Novartis, a leader in cancer therapies, to empower patients and care teams to manage their breast cancer treatment journey with best-in-class digital innovation,” said Pierre Leurent, CEO, Voluntis. “This new collaboration also reinforces Theraxium Oncology as the backbone for digital therapeutics that support patients and their care teams across the spectrum of cancer care.”
Neha writes articles on sectors including medicine, food, materials, and science & technology. A qualified statistician, she has the ability to observe and analyze the trends in global markets and write compelling articles that help CXOs in decision making. She is a bookworm and loves to read fiction, lifestyle, science and technology. Neha comes with 6 years of experience in content writing and editing that involves blog writing, preparation of study materials and OERs.